Abstract:
Degradable polyacetal polymers and functionalized degradable polyacetal polymers have properties favorable for use in pharmaceutical and biomedical applications. The degradable polyacetal polymers are relatively stable at physiological pH with favorable biodistribution profiles, and degrade readily in low pH conditions. Conjugates of the polymers with drugs, especially anticancer drugs, and use for treatment of cancer.
Abstract:
A process for producing an acetal copolymer by copolymerizing trioxane with a cyclic ether copolymerizable therewith, wherein the cyclic ether is a mixture of a fresh cyclic ether wherein the content of a peroxide derived therefrom is at most 15 wt. ppm in terms of hydrogen peroxide and at least one sterically hindered phenol added in a quantity of 10-500 wt. ppm based on the ether. This process enables a highly heat-stable acetal copolymer to be produced in a stabilized manner, and also enables deactivation of the catalyst and stabilization of the unstable polymer ends to be effected in a stabilized manner after the copolymerization.
Abstract:
A process for producing a high-molecular-weight polydioxolane which comprises the steps of polymerizing 1,3-dioxolane in the presence of a polymerization catalyst containing a heteropolyacid and neutralizing the obtained reaction product with an organic amine and/or ammonia. A hydrophilic film which contains the polydioxolane, is made from a resin having a specified molecular weight, and has specified crystallinity and spherulite size. A cold-water-degradable film contains the polydioxolane and is produced by forming a resin having specified molecular weight into film under specified molding conditions or by giving a specified thermal history to the film of this polymer.
Abstract:
A process for the manufacture of bioerodible poly(orthoester)s and polyacetals containing beneficial agents having a hydroxyl functionality of two or more and their fabrication into controlled release dosage forms having a reproducible delivery of the beneficial agent into the biological environment of use are disclosed.
Abstract:
A water soluble polyoxymethylene copolymer is described. In one embodiment, the polyoxymethylene copolymer is a liquid at 35°C and is water soluble. The polyoxymethylene copolymer may have a comonomer content of greater than about 60% by weight, such as greater than about 70% by weight, such as greater than about 80% by weight. The copolymer is usually formed using a chain transfer agent. The polyoxymethylene copolymer can be formed so as to have a relatively low molecular weight and have a relatively great amount of end groups or terminal groups. For instance, the copolymer may contain end groups in an amount greater than 300 mmol/kg.
Abstract:
The present disclosure is directed to improved poly(arylene ether ketone) powders for use in laser sintering, powder coating, compression molding, or transfer molding.
Abstract:
Disclosed are polyurea compositions comprising the reaction products of a polyformal-isocyanate prepolymer and a curing agent comprising an amine. The compositions are useful as sealants in aerospace applications.
Abstract:
A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L p . Each occurrence of D is independently a tubulysin compound having a molecular weight D and L p are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.